Kaletra en es it fr

Kaletra Brand names, Kaletra Analogs

Kaletra Brand Names Mixture

  • Kaletra (Lopinavir + Ritonavir)

Kaletra Chemical_Formula


Kaletra RX_link


Kaletra fda sheet

Kaletra FDA

Kaletra msds (material safety sheet)

Kaletra MSDS

Kaletra Synthesis Reference

No information avaliable

Kaletra Molecular Weight

720.946 g/mol

Kaletra Melting Point

No information avaliable

Kaletra H2O Solubility

Practically insoluble

Kaletra State


Kaletra LogP


Kaletra Dosage Forms

Capsule (100 mg); Solution (80 mg/mL of ritonavir)

Kaletra Indication

Indicated in combination with other antiretroviral agents for the treatment of HIV-infection.

Kaletra Pharmacology

Ritonavir is a protease inhibitor with activity against Human Immunodeficiency Virus Type 1 (HIV-1). Protease inhibitors block the part of HIV called protease. HIV-1 protease is an enzyme required for the proteolytic cleavage of the viral polyprotein precursors into the individual functional proteins found in infectious HIV-1. Ritonavir binds to the protease active site and inhibits the activity of the enzyme. This inhibition prevents cleavage of the viral polyproteins resulting in the formation of immature non-infectious viral particles. Protease inhibitors are almost always used in combination with at least two other anti-HIV drugs.

Kaletra Absorption

The absolute bioavailability of ritonavir has not been determined.

Kaletra side effects and Toxicity

Human experience of acute overdose with NORVIR is limited. One patient in clinical trials took NORVIR 1500 mg/day for two days. The patient reported paresthesias which resolved after the dose was decreased. A post-marketing case of renal failure with eosinophilia has been reported with ritonavir overdose. The approximate lethal dose was found to be greater than 20 times the related human dose in rats and 10 times the related human dose in mice.

Kaletra Patient Information

No information avaliable

Kaletra Organisms Affected

Human immunodeficiency virus